• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001

    Gabrielle Lakusta
    Oct. 18, 2018 09:10AM PST
    Pharmaceutical Investing

    Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company. As quoted in the press release: The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or …

    Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company.

    As quoted in the press release:

    The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or apolipoprotein C-III by administering a pharmaceutical composition comprising omega-3 fatty acids comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA).

    “Recent developments in the cardiovascular space have placed renewed focus on MAT9001, our proprietary and purposefully designed omega-3 product. Over the past few years, we continued to be diligent in the prosecution of important intellectual property covering our MAT9001 product and the ongoing expansion of our intellectual property portfolio is an integral aspect of our development strategy. Given the clinical data generated from a head-to-head study of MAT9001 demonstrating superiority versus Vascepa® (icosapent ethyl) in reducing triglycerides, total and non-HDL cholesterol, apolipoproteins and PCSK9 levels, we are very excited about the prospects for our potential best-in-class drug in this emerging drug class. We are committed to further exploring a variety of interesting and value-creating opportunities for the development and ultimate commercialization of MAT9001,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas.

    Click here to read the full press release.

    matinas biopharmanyse:mtnbu.s. patent and trademark office
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×